Can a new injection tame lupus when standard care fails?

This early-phase trial is testing an investigational drug called ACG102, given by intravenous infusion, in people with refractory active systemic lupus erythematosus (SLE) — a form of lupus that has not responded well to standard treatments. The main goals are to check the drug's safety, tolerability, and how the body processes it, while also looking for early signs that it might reduce disease activity. About 13 adults with lupus will receive multiple infusions at different dose levels. The study is a first step to see if ACG102 is worth developing further as a potential treatment for hard-to-control lupus.